JP2002503484A5 - - Google Patents

Download PDF

Info

Publication number
JP2002503484A5
JP2002503484A5 JP2000531596A JP2000531596A JP2002503484A5 JP 2002503484 A5 JP2002503484 A5 JP 2002503484A5 JP 2000531596 A JP2000531596 A JP 2000531596A JP 2000531596 A JP2000531596 A JP 2000531596A JP 2002503484 A5 JP2002503484 A5 JP 2002503484A5
Authority
JP
Japan
Prior art keywords
virus
composition
layer
concentration
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000531596A
Other languages
English (en)
Japanese (ja)
Other versions
JP4358434B2 (ja
JP2002503484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/001873 external-priority patent/WO1999041416A2/en
Publication of JP2002503484A publication Critical patent/JP2002503484A/ja
Publication of JP2002503484A5 publication Critical patent/JP2002503484A5/ja
Application granted granted Critical
Publication of JP4358434B2 publication Critical patent/JP4358434B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000531596A 1998-02-17 1999-02-12 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法 Expired - Fee Related JP4358434B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US09/024,462 1998-02-17
US7964398A 1998-05-15 1998-05-15
US09/079,643 1998-05-15
PCT/US1999/001873 WO1999041416A2 (en) 1998-02-17 1999-02-12 Compositions comprising viruses and methods for concentrating virus preparations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006030336A Division JP2006166925A (ja) 1998-02-17 2006-02-07 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法

Publications (3)

Publication Number Publication Date
JP2002503484A JP2002503484A (ja) 2002-02-05
JP2002503484A5 true JP2002503484A5 (https=) 2009-04-30
JP4358434B2 JP4358434B2 (ja) 2009-11-04

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000531596A Expired - Fee Related JP4358434B2 (ja) 1998-02-17 1999-02-12 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
JP2006030336A Withdrawn JP2006166925A (ja) 1998-02-17 2006-02-07 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
JP2010156257A Withdrawn JP2010213727A (ja) 1998-02-17 2010-07-08 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006030336A Withdrawn JP2006166925A (ja) 1998-02-17 2006-02-07 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法
JP2010156257A Withdrawn JP2010213727A (ja) 1998-02-17 2010-07-08 ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法

Country Status (24)

Country Link
EP (4) EP1054955B1 (https=)
JP (3) JP4358434B2 (https=)
KR (5) KR100912362B1 (https=)
CN (2) CN100374551C (https=)
AR (3) AR020054A1 (https=)
AT (3) ATE371020T1 (https=)
AU (1) AU757976B2 (https=)
BR (1) BR9908015A (https=)
CA (2) CA2723040A1 (https=)
CO (1) CO4820440A1 (https=)
DE (3) DE69942708D1 (https=)
DK (1) DK1054955T3 (https=)
ES (2) ES2290613T3 (https=)
HU (1) HU226015B1 (https=)
ID (1) ID28298A (https=)
IL (2) IL137510A0 (https=)
MY (1) MY141641A (https=)
NO (1) NO20004104L (https=)
PE (1) PE20000265A1 (https=)
PL (1) PL197747B1 (https=)
PT (1) PT1054955E (https=)
SK (1) SK11842000A3 (https=)
TW (1) TWI232107B (https=)
WO (1) WO1999041416A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
DE69940354D1 (de) * 1998-11-16 2009-03-12 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
JP2002241311A (ja) * 2000-12-12 2002-08-28 Japan Tobacco Inc 界面活性剤を含む医薬組成物
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
AR038153A1 (es) * 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
EP1815029A4 (en) 2004-11-03 2009-06-10 Introgen Therapeutics Inc NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
CA2590943C (en) 2004-12-13 2013-10-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
EP2618838A1 (en) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
JP6029651B2 (ja) * 2011-04-29 2016-11-24 オンコリティクス バイオテク,インコーポレーテッド ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5770952B2 (ja) 2012-03-12 2015-08-26 クルセル ホランド ベー ヴェー 改変末端を有する組換えアデノウイルスのバッチ
EA026504B1 (ru) 2012-03-22 2017-04-28 Круселл Холланд Б.В. Вакцина против rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP6469081B2 (ja) 2013-04-25 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsvfポリペプチド
MY171210A (en) 2013-06-17 2019-10-02 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f polypeptides
SG11201609908VA (en) * 2014-05-28 2016-12-29 Agency Science Tech & Res Virus reduction method
WO2016166088A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
PH12022552125A1 (en) 2016-04-05 2023-04-12 Janssen Vaccines & Prevention Bv Stabilized soluble pre-fusion rsv f proteins
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
KR102307065B1 (ko) 2016-06-20 2021-09-30 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
WO2019053109A1 (en) 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
JP2022513025A (ja) 2018-11-13 2022-02-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化された融合前rsv fタンパク質
EP3990031A4 (en) * 2019-06-28 2023-08-09 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
AU2021237818A1 (en) * 2020-03-19 2022-09-29 Ferring Ventures Ltd. Temperature-responsive virus storage system
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (https=) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Similar Documents

Publication Publication Date Title
JP2002503484A5 (https=)
CA2320419A1 (en) Compositions comprising viruses and methods for concentrating virus preparations
EP0199698B1 (fr) Procédé d'extraction et de purification de protéines issues de milieux de culture les produisant
Savithri et al. The self-assembly of the cowpea strain of southern bean mosaic virus: formation of T= 1 and T= 3 nucleoprotein particles
US5371196A (en) Process for producing secretory immunoglobulin A preparations
CN111358941A (zh) 含包封有plp依赖性酶及其辅助因子的红细胞的药物组合物
JPS608865B2 (ja) 生体高分子、低分子物質を可逆的または不可逆的に固定し得る陽イオン性物質
Knippers et al. A coat protein from bacteriophage fd: I. Hydrodynamic measurements and biological characterization
JPS63105693A (ja) 細胞から親油性タン白の抽出方法
EP4417193A1 (en) Use of milk exosome in preparation of drug carrier
JPS6136228A (ja) 肝炎表面抗原の精製方法
CA2314610C (fr) Procede de preparation par filtration d'une solution de facteur viii securisee viralement
WO2014015816A1 (zh) 一种去除疫苗中宿主dna的方法
JP2007523883A5 (https=)
EP0252588A2 (en) Process for the isolation and purification of P. falciparum CS protein expressed in recombinant E. coli, and its use as a vaccine
Hsu et al. Assembly of southern bean mosaic virus from its two subviral intermediates
JPH06279317A (ja) A型肝炎(hav)の抗原およびワクチンの製造方法
JPS6034916A (ja) 第1x因子および他のビタミンk依存性タンパク質の高純度精製
CN100480378C (zh) 生产乳过氧化物酶的方法
JPS6232881A (ja) カンデイダ・ボイデイニからギ酸脱水素酵素を精製し、必要により回収する方法およびギ酸脱水素酵素含有生成物
EP2699248B1 (fr) Procédé de préparation d'un produit plasmatique déplété en un ou plusieurs facteurs thrombogenes
EP0100366A1 (en) Agent for treating allergic disease, immunity complex disease, and tumour
JP2926722B2 (ja) アルブミン製剤及びその製造方法
JPS61103895A (ja) HBsAgの精製方法
JPH0625011A (ja) ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法